Omega-3-carboxylic Acids Patent Expiration

Omega-3-Carboxylic Acids is Used for lowering high levels of triglycerides in adult patients. It was first introduced by Astrazeneca Pharmaceuticals Lp in its drug Epanova on May 5, 2014.


Omega-3-carboxylic Acids Patents

Given below is the list of patents protecting Omega-3-carboxylic Acids, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Epanova US10117844 DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form Jan 04, 2033 Astrazeneca
Epanova US9050308 DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form Jan 04, 2033 Astrazeneca
Epanova US9050309 DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form Jan 04, 2033 Astrazeneca
Epanova US7960370 Type A gelatin capsule containing PUFA in free acid form Dec 20, 2026 Astrazeneca
Epanova US8383678 Type a gelatin capsule containing PUFA in free acid form Feb 07, 2025 Astrazeneca
Epanova US9012501 Type A gelatin capsule containing PUFA in free acid form Feb 07, 2025 Astrazeneca
Epanova US9132112 Type A gelatin capsule containing PUFA in free acid form Feb 07, 2025 Astrazeneca
Epanova US5792795 Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids May 13, 2020

(Expired)

Astrazeneca
Epanova US5948818 Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids May 13, 2020

(Expired)

Astrazeneca



Omega-3-carboxylic Acids's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List